Novo Nordisk Eyes 15 Million New Patients Thanks to Medicare

• Novo Nordisk aims to gain 15 million new patients with Medicare's obesity treatment coverage.
• Medicare coverage could significantly expand the market for obesity medications.
• Novo Nordisk plans to offset lower prices with increased prescription volumes and new products.
• The company is focused on closing the market share gap with Eli Lilly in the GLP-1 space.

Very Nice, Medicare Covers Obesity Medicines

Jagshemash! Borat Sagdiyev here, reporting live from the capitalist paradise of the United States. I have just learned that Medicare, the system for old people's health, will now pay for medicines to help people lose weight. This is fantastic news! In my country of Kazakhstan, we just tell people to run from bear. Here, you get pill. Is very nice.

Fifteen Million New Patients, I Like

The big cheese at Novo Nordisk, Mike Doustdar, says they want to grab around 15 million new patients. Fifteen million! That's almost as many people as live in my entire village. He says Medicare covers around 67 million Americans, but only some need the weight-loss magic. This is good for Novo Nordisk, good for the patients, and maybe even good for my chances of finding a wife who is not my sister. Speaking of companies doing well, have you heard about Lithia Motors Pumps Brakes on Chinese Auto Sales in the U.S. Market? They are also making smart moves in this crazy capitalist world. Very excite.

Novo vs. Lilly: Great Success or Wawaweewa?

There is a big fight between Novo Nordisk and Eli Lilly. Like when I wrestled my neighbor Nursultan Tulyakbay, but with more money involved. Lilly has more of the market now, about 60.5%, while Novo has only 39.1%. Doustdar says they will do better with their new pill. He says their pill makes people lose more weight, 16.6%, compared to Lilly's pill, which only makes them lose 12.4%. Is like comparing a good horse to a very good goat.

The Magic Pill: Is Potent

Doustdar is betting on their new pill to win back the market. He says it's more effective than Lilly's, based on the clinical trials. More effective means people lose more weight. More weight loss means more happiness. More happiness means… well, maybe I can finally afford a new tracksuit.

Higher Dose, Higher Hope

Novo is also launching a higher dose of their other medicine, Wegovy. The higher dose helps people lose even more weight, about 21%. This is similar to Lilly's Zepbound. Doustdar hopes that people will see that the two medicines are now equally good. Is like saying my mustache is as impressive as my neighbor's. Maybe.

Slowly But Surely, Like My Donkey

Doustdar is not expecting things to change overnight. He says getting access to these treatments will be slow, like trying to teach a donkey to drive a car. But he is hopeful that, in time, more people will get the help they need. And maybe, just maybe, I can convince my producer to pay for my own Wegovy prescription. Chenqui!